1,3-dibutyl-7-(2-hydroxy-propyl)-3,7-dihydro-purine-2,6-dione | 109254-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,3-dibutyl-7-(2-hydroxy-propyl)-3,7-dihydro-purine-2,6-dione
• 英文别名: 1,3-Dibutyl-7-(2-hydroxy-propyl)-3,7-dihydro-purin-2,6-dion；1,3-di-n-butyl-7-(2-hydroxypropyl)xanthine；1,3-Dibutyl-7-(2-hydroxypropyl)purine-2,6-dione
• CAS: 109254-94-6
• 化学式: C₁₆H₂₆N₄O₃
• 分子量: 322.407
• InChiKey: DBDWFTREQDPFIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  78.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases
  申请人：Beecham Wuelfing GmbH & Co KG

  公开号：EP0267676A2

  公开（公告）日：1988-05-18

  A method for the treatment of cerebral vascular and neuronal degenerative disorders associated with learning, memory and cognitive dysfunctions including cerebral senility, multi-infarct dementia and senile dementia of the Alzheimer type and/or peripheral vascular disease and/or proliferative skin disease in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine or a pharmaceutically acceptable salt thereof.

  一种治疗与学习、记忆和认知功能障碍有关的脑血管和神经元退行性疾病（包括脑衰老、多梗塞性痴呆和阿尔茨海默型老年痴呆和/或外周血管疾病和/或哺乳动物（如人类）的增生性皮肤病）的方法，该方法包括向需要此类治疗的哺乳动物施用有效量的1,3-二正丁基-7-（2-氧丙基）黄嘌呤或其药学上可接受的盐。
• Xanthine derivatives used in asthma
  申请人：Beecham Group p.l.c.

  公开号：EP0421587A2

  公开（公告）日：1991-04-10

  A method for the treatment and/or prophylaxis of disorders associated with increased number of eosinophils and allergic disorders associated with atopy which method comprises the administration of an effective, non-toxic amount of a compound formula (I), as defined herein, to a human or non-human mammal in need of such treatment.

  一种治疗和/或预防与嗜酸性粒细胞数量增加有关的疾病和与过敏症有关的过敏性疾病的方法，该方法包括向需要治疗的人类或非人类哺乳动物施用有效、无毒量的如本文所定义的式 (I) 化合物。
• Xanthinederivatives, process for their preparation and their pharmaceutical use
  申请人：SmithKline Beecham Pharma GmbH

  公开号：EP0389282B1

  公开（公告）日：2002-02-20
• USE OF XANTHINE-DERIVATIVES AS INHIBITORS OF INDUCED BLOOD EOSINOPHILIA
  申请人：Beecham Group p.l.c.

  公开号：EP0485495A1

  公开（公告）日：1992-05-20
• ENOXIMONE FORMULATIONS AND THEIR USE IN THE TREATMENT OF PDE-III MEDIATED DISEASES
  申请人：MYOGEN, INC.

  公开号：EP1776108A1

  公开（公告）日：2007-04-25